Serum Institute may alter covid shot to tackle mutant strain

  • WHO expressed concerns over jab’s effectiveness against S. African strain
  • on Monday and Tuesday, SAGE reviewed the evidence on jab’s effectiveness on new SARS CoV-2 variants

Neetu Chandra Sharma
Updated9 Feb 2021, 10:51 PM IST
Named as covishield in India, the Oxford-AstraZeneca vaccine has been rolled out in the country but is yet to receive a green signal for global use through COVAX
Named as covishield in India, the Oxford-AstraZeneca vaccine has been rolled out in the country but is yet to receive a green signal for global use through COVAX(REUTERS)

The composition of the vaccine developed by the University of Oxford and British pharma major AstraZeneca may have to be adjusted by vaccine manufacturer Serum Institute of India, after the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) expressed concerns over the effectiveness of the vaccine against the South African mutant coronavirus strain.

On Monday and Tuesday, SAGE reviewed the evidence on the vaccine’s effectiveness on new SARS CoV-2 variants, before making significant recommendations. Earlier, South Africa decided to stop the roll out of the Oxford-AstraZeneca vaccine after preliminary clinical trial findings published by the Wits Vaccines and Infectious Diseases Analytics Research Unit indicated that it offered minimal protection against the mild-moderate covid-19 infection from the B.1.351 variant of the coronavirus first identified in the country in November. The study involved around 2,000 volunteers.

COVAX, a global joint initiative of Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and WHO, aimed at providing equal access to covid-19 vaccines in more than 92 low- and middle-income countries, said it is vitally important to determine the vaccine’s effectiveness when it comes to preventing more severe illnesses caused by the B.1.351 variant.

The development assumes significance for the Adar Poonawalla-led Serum Institute of India (SII), as COVAX has signed advance purchase agreements with AstraZeneca and SII, and has announced plans to distribute nearly 350 million doses in the first half of the year.

Though the Oxford-AstraZeneca vaccine, branded as Covishield in India, was rolled out in the country, it is yet to receive a green signal for global use by COVAX. “We expect a decision this month from WHO on whether the vaccines will be granted emergency use listing as well as SAGE recommendation on its optimal use,” COVAX said.

The new playbook from Poonawalla’s firm may now involve booster shots and adapted vaccines.

With the virus changing, COVAX has further warned that “manufacturers must be prepared to adjust to the SARS-CoV-2 viral evolution, including potentially providing future booster shots and adapted vaccines, if found to be scientifically necessary. Trials must be designed and maintained to allow any changes in efficacy to be assessed, and to be of sufficient scale and diversity to enable clear interpretation of results,” the WHO said.

Mint reached out to Poonawalla, but he did not comment.

India has only one mutant strain of coronavirus, the UK variant, circulating. The government has cited studies to say that Bharat Biotech’s Covaxin works against the mutant strain. It has, however, said that the surveillance for mutations in the virus will be increased after the vaccine efficacy issue was brought to its notice by South Africa.

Catch all the Business News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

MoreLess
First Published:9 Feb 2021, 10:51 PM IST
Business NewsNewsIndiaSerum Institute may alter covid shot to tackle mutant strain

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    Tata Steel share price

    150.55
    11:00 AM | 8 NOV 2024
    -0.35 (-0.23%)

    Indian Hotels Company share price

    725.00
    11:00 AM | 8 NOV 2024
    41.4 (6.06%)

    Tata Motors share price

    810.55
    11:00 AM | 8 NOV 2024
    -9.25 (-1.13%)

    Indian Oil Corporation share price

    141.60
    11:00 AM | 8 NOV 2024
    -2.6 (-1.8%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Page Industries share price

    47,174.40
    10:42 AM | 8 NOV 2024
    2068.9 (4.59%)

    National Aluminium Company share price

    242.75
    10:43 AM | 8 NOV 2024
    4.2 (1.76%)

    Apollo Hospitals Enterprise share price

    7,442.85
    10:42 AM | 8 NOV 2024
    18.25 (0.25%)

    City Union Bank share price

    180.85
    10:42 AM | 8 NOV 2024
    0 (0%)
    More from 52 Week High

    Great Eastern Shipping Company share price

    1,213.75
    10:42 AM | 8 NOV 2024
    -77.2 (-5.98%)

    GMM Pfaudler share price

    1,295.00
    10:42 AM | 8 NOV 2024
    -79.9 (-5.81%)

    Rail Vikas Nigam share price

    452.00
    10:43 AM | 8 NOV 2024
    -25.55 (-5.35%)

    IRCON International share price

    204.35
    10:43 AM | 8 NOV 2024
    -10.75 (-5%)
    More from Top Losers

    Motilal Oswal Financial Services share price

    1,012.85
    10:43 AM | 8 NOV 2024
    78.65 (8.42%)

    ITI share price

    287.40
    10:43 AM | 8 NOV 2024
    20.75 (7.78%)

    Indian Hotels Company share price

    724.00
    10:43 AM | 8 NOV 2024
    40.4 (5.91%)

    Sterlite Technologies share price

    129.25
    10:43 AM | 8 NOV 2024
    7.15 (5.86%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      78,575.000.00
      Chennai
      78,581.000.00
      Delhi
      78,733.000.00
      Kolkata
      78,585.000.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.92/L0.00
      Chennai
      100.80/L0.00
      Kolkata
      104.95/L0.00
      New Delhi
      94.77/L0.00

      Popular in News

        HomeMarketsPremiumInstant LoanMint Shorts